Comparison
Retatrutide vs CagriSema
Retatrutide alongside CagriSema, compared on developer, mechanism, administration, development stage, trial population, reported efficacy, study duration and regulatory status.
Side by side
Comparison table
| Field | Retatrutide | CagriSema |
|---|---|---|
| Developer | Eli Lilly and Company | Novo Nordisk |
| Mechanism | GLP-1 / GIP / Glucagon triple agonist | Amylin analogue + GLP-1 agonist |
| Administration | Once-weekly subcutaneous | Once-weekly subcutaneous |
| Development Stage | Phase 3 | Phase 3 / regulatory submission |
| Studied Population | Obesity ± type 2 diabetes | Obesity, type 2 diabetes |
| Regulatory Status | Investigational | Investigational |
Cross-trial comparisons should be interpreted cautiously because study populations, trial designs, treatment durations and endpoints may differ.
Weekly briefing
The Retatrutide Report
The most important retatrutide clinical trial, research and regulatory developments, once a week.
No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.